Proteomic Network Analysis of Alzheimer’s Disease Cerebrospinal Fluid Reveals Alterations Associated with APOE ε4 Genotype and Atomoxetine Treatment

Alzheimer’s disease (AD) is currently defined at the research level by the aggregation of amyloid-β (Aβ) and tau proteins in brain. While biofluid biomarkers are available to measure Aβ and tau pathology, few biomarkers are available to measure the complex pathophysiology that is associated with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Dammer, Eric B., Shantaraman, Anantharaman, Ping, Lingyan, Duong, Duc M., Gerasimov, Ekaterina S., Ravindran, Suda Parimala, Gudmundsdottir, Valborg, Frick, Elisabet A., Gomez, Gabriela T., Walker, Keenan A., Emilsson, Valur, Jennings, Lori L., Gudnason, Vilmundur, Western, Daniel, Cruchaga, Carlos, Lah, James J., Wingo, Thomas S., Wingo, Aliza P., Seyfried, Nicholas T., Levey, Allan I., Johnson, Erik C.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635242/
https://www.ncbi.nlm.nih.gov/pubmed/37961720
http://dx.doi.org/10.1101/2023.10.29.23297651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635242/
https://www.ncbi.nlm.nih.gov/pubmed/37961720
http://dx.doi.org/10.1101/2023.10.29.23297651

Ejemplares similares